A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in
participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors
(NETs) as a potential new way to help diagnose NETs.